Miriam Berg, APRN
Nurse Practitioner · Grove City, OHNPI 1205312006
Payments from drug & device makers
Across 142 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$668
- Novo Nordisk$225
- Lilly USA, LLC$207
- Gilead$158
- AstraZeneca$110
- Napo Pharmaceuticals Inc$109
- plus $789 from 18 others
What the payments were for
- Food & beverage$2,266100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $668 |
| Novo Nordisk | 20 | $225 |
| Lilly USA, LLC | 14 | $207 |
| Gilead | 6 | $158 |
| AstraZeneca | 7 | $110 |
| Napo Pharmaceuticals Inc | 5 | $109 |
| Merck | 5 | $103 |
| Viiv Healthcare Company | 4 | $95 |
| Boehringer Ingelheim | 5 | $94 |
| Exact Sciences | 3 | $88 |
| Abbott | 4 | $78 |
| Astellas Pharma US Inc | 2 | $51 |
| Bayer | 3 | $46 |
| Dynavax Technologies Corporation | 2 | $35 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Pfizer | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$2,266 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $44,368 |
| JardianceEmpagliflozin | 36 | $43,636 |
| TrulicityDulaglutide | 31 | $38,499 |
| EliquisApixaban | 22 | $24,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $20,263 |
| XareltoRivaroxaban | 11 | $16,573 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,253 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,515 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $2,783 |
| Atorvastatin Calcium | 236 | $2,422 |
| Celecoxib | 11 | $2,081 |
| Gabapentin | 92 | $1,560 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $1,520 |
| SynthroidLevothyroxine Sodium | 18 | $1,486 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $225 | $44,36832 claims |
| Boehringer IngelheimJardiance | $94 | $43,63636 claims |
| Lilly USA, LLCTrulicity | $207 | $38,49931 claims |
| PfizerEliquis | $18 | $24,01722 claims |
| GSKTrelegy Ellipta | $20 | $20,26320 claims |
| Johnson & JohnsonXarelto | $32 | $16,57311 claims |
| AstraZenecaBreztri Aerosphere | $110 | $11,25319 claims |
| MerckJanumet Xr | $103 | $5,51511 claims |
| AbbVieSynthroid | $668 | $1,48618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Grove City
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.